Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase III Study of Letrozole in Heavily Pretreated Recurrent Ovarian Cancer
2019-001623-12Phase 3Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of letrozole in ovarian cancer and Serous Papillary Cystadenocarcinoma (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Proportion of patients alive at 12 months. Started Jun 2021; status: terminated.
02
Drugs
letrozole
03
Conditions
ovarian cancerSerous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on 2019-001623-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001623-12.